•
Dec 31, 2023

Waters Q4 2023 Earnings Report

Waters' Q4 2023 financial performance was reported, revealing a decrease in sales but improved margins and EPS within guidance.

Key Takeaways

Waters Corporation reported Q4 2023 sales of $819 million, a 4.5% decrease as reported. However, the company's operational excellence led to gross margin and adjusted operating margin expansion. Non-GAAP EPS was $3.62, at the high end of guidance, while GAAP EPS was $3.65.

Sales declined by 4.5% as reported, totaling $819 million.

Gross margin expanded by 170 basis points due to operational excellence.

Adjusted operating margin increased by 120 basis points.

Non-GAAP EPS reached $3.62, aligning with the upper range of expectations; GAAP EPS was $3.65.

Total Revenue
$819M
Previous year: $859M
-4.5%
EPS
$3.62
Previous year: $3.84
-5.7%
Pharma Market Sales
463,698,000%
0
Industrial Market Sales
260,249,000%
Previous year: 8%
+3253112400.0%
Academic & Gov Sales
95,527,000%
Previous year: 1%
+9552699900.0%
Gross Profit
$489M
Previous year: $510M
-4.2%
Cash and Equivalents
$396M
Previous year: $481M
-17.7%
Free Cash Flow
$189M
Total Assets
$4.63B
Previous year: $3.28B
+41.0%

Waters

Waters

Waters Revenue by Segment

Waters Revenue by Geographic Location

Forward Guidance

The Company expects first quarter 2024 organic constant currency sales growth to be in the range of -11% to -9%. Currency translation is expected to decrease first quarter sales growth by approximately 1%. The Wyatt transaction is expected to increase first quarter reported sales growth by 3.5%.

Revenue & Expenses

Visualization of income flow from segment revenue to net income